[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339628-105":59,"doc-detail-339628-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-rapidly-changing-field-of-predictive-biomarkers-of-non-small-cell-lung-cancer-review","The rapidly changing field of predictive biomarkers of non-small cell lung cancer - Review","","The review analyzes how predictive biomarkers support personalized oncology in non-small cell lung cancer (NSCLC), emphasizing targeted therapy and immune-based approaches. It summarizes key molecular targets within EGFR signaling, including activating and resistance EGFR mutations and alterations in KRAS, BRAF, ALK, ROS1, RET, and MET. It also addresses tumor microenvironment and anti-tumor immunity, including immune checkpoint blockade and PD-L1 expression. Diagnostic constraints around limited sample quantity and quality are discussed alongside testing standardization and optimal material use.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-rapidly-changing-field-of-predictive-biomarkers-of-non-small-cell-lung-cancer-review/339628/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-rapidly-changing-field-of-predictive-biomarkers-of-non-small-cell-lung-cancer-review/339628.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are predictive biomarkers important in NSCLC treatment?","Question",{"text":112,"@type":113},"Predictive biomarkers help match patients to targeted therapies with the highest potential of success and can indicate likely effectiveness of specific therapeutic approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which genetic alterations are highlighted as relevant targets in NSCLC?",{"text":117,"@type":113},"The review highlights EGFR pathway targets, including activating and resistance EGFR mutations, as well as alterations of KRAS and BRAF. It also notes targetable rearrangements such as ALK and ROS1, RET gene rearrangements, and alterations of MET.",{"name":119,"@type":110,"acceptedAnswer":120},"How do immune checkpoint therapies relate to biomarkers and testing?",{"text":121,"@type":113},"The review discusses how anti–PD1/PD-L1 immune checkpoint blockade may reactivate tumor killing and lead to tumor regression, with therapeutic responses potentially correlating with tumor PD-L1 expression. It also emphasizes the need for appropriate biomarker testing despite limited biopsy/cytology sample quantity and quality.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339628,1790741726,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","TYPE Review  \nPUBLISHED 17 June 2024  \nDOI 10.3389/pore.2024.1611733  \nOPEN ACCESS  \nEDITED BY  \nNora Bittner,  \nNational Koranyi Institute of TB and Pulmonology, Hungary  \n*CORRESPONDENCE  \nLászló József Tóth,  \n [tothlasz@med.unideb.hu](tothlasz@med.unideb.hu)  \nRECEIVED 18 February 2024  \nACCEPTED 04 June 2024  \nPUBLISHED 17 June 2024  \nCITATION  \nTóth LJ, Mokánszki A and Méhes G (2024), The rapidly changing ﬁeld of predictive biomarkers of non-small cell lung cancer.  \nPathol. Oncol. Res. 30:1611733 .  \ndoi: 10.3389/pore.2024.1611733  \nCOPYRIGHT  \n© 2024 Tóth, Mokánszki and Méhes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe rapidly changing ﬁeld of predictive biomarkers of non-small cell lung cancer  \nLászló József Tóth*, Attila Mokánszki and Gábor Méhes Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary  \nLung cancer is a leading cause of cancer-related death worldwide in both men and women, however mortality in the US and EU are recently declining in parallel with the gradual cut of smoking prevalence. Consequently, the relative frequency of adenocarcinoma increased while that of squamous and small cell carcinomas declined. During the last two decades a plethora of targeted drug therapies have appeared for the treatment of metastasizing non-small cell lung carcinomas (NSCLC) . Personalized oncology aims to precisely match patients to treatments with the highest potential of success. Extensive research is done to introduce biomarkers which can predict the effectiveness of a speciﬁc targeted therapeutic approach. The EGFR signaling pathway includes several sufﬁcient targets for the treatment of human cancers including NSCLC. Lung adenocarcinoma may harbor both activating and resistance mutations of the EGFR gene, and further, mutations of KRAS and BRAF oncogenes. Less frequent but targetable genetic alterations include ALK, ROS1, RET gene rearrangements, and various alterations of MET proto-oncogene. In addition, the importance of anti-tumor immunity and of tumor microenvironment has become evident recently. Accumulation of mutations generally trigger tumor speciﬁc immune defense, but immune protection may be upregulated as an aggressive feature. The blockade of immune checkpoints results in potential reactivation of tumor cell killing and induces signiﬁcant tumor regression in various tumor types, such as lung carcinoma. Therapeutic responses to anti PD1-PD-L1 treatment may correlate with the expression of PD-L1 by tumor cells. Due to the wide range of diagnostic and predictive features in lung cancer a plenty of tests are required from a single small biopsy or cytology specimen, which is challenged by major issues of sample quantity and quality. Thus, the efﬁcacy of biomarker testing should be warranted by standardized policy and optimal material usage. In this review we aim to discuss major targeted therapy-related biomarkers in NSCLC and testing possibilities comprehensively.  \nKEYWORDS  \nNSCLC, driver oncogenes, immune checkpoint inhibitor, gene fusion, biomarker  \nPathology & Oncology Research 01 Published by Frontiers  \nIntroduction  \nPrimary lung cancer used to be a rare tumor in the past, however today it is the most common cause of cancer mortality worldwide. In 2020, lung carcinoma was the second most common malignancy, with around 2.2 million newly diagnosed cases. Moreover, with 1.796 million cases, it was the number one cause of cancer deaths [1] . The incidence in both of US and EU is now declining, that follows the trend of shrinking smoking prevalence [2] . The inci","cbCaiatnAoLtRn2o","https://ap.wps.com/l/cbCaiatnAoLtRn2o","pdf",1645886,27,"English","# Introduction\n## Epidemiology and histological shifts in lung cancer\n# Targeted therapy and biomarker rationale in NSCLC\n## EGFR signaling targets and key genetic alterations\n## Immune checkpoint pathways and PD-L1-linked responses\n# Biomarker testing strategies and practical constraints\n## Sample quantity/quality considerations\n## Standardized policies and material optimization","[{\"question\":\"Why are predictive biomarkers important in NSCLC treatment?\",\"answer\":\"Predictive biomarkers help match patients to targeted therapies with the highest potential of success and can indicate likely effectiveness of specific therapeutic approaches.\"},{\"question\":\"Which genetic alterations are highlighted as relevant targets in NSCLC?\",\"answer\":\"The review highlights EGFR pathway targets, including activating and resistance EGFR mutations, as well as alterations of KRAS and BRAF. It also notes targetable rearrangements such as ALK and ROS1, RET gene rearrangements, and alterations of MET.\"},{\"question\":\"How do immune checkpoint therapies relate to biomarkers and testing?\",\"answer\":\"The review discusses how anti–PD1/PD-L1 immune checkpoint blockade may reactivate tumor killing and lead to tumor regression, with therapeutic responses potentially correlating with tumor PD-L1 expression. It also emphasizes the need for appropriate biomarker testing despite limited biopsy/cytology sample quantity and quality.\"}]","The rapidly changing field of predictive biomarkers of non-small cell lung cancer - Review | PDF",1790031305,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7ad3dd2a5f9f4741bb15628b73d7855.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b69c399285abbc8f3cb8680de7490585.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/369940d02a45f247e15618bc87d42fb7.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9537810cd49c05f43964f4b02f0885ff.webp",980,1385]